Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. provides an annual update on its inflammatory and immunology biologics pipeline, led by zumilokibart (APG777) for atopic dermatitis and asthma. The company reports strong Phase 2 APEX Part A results in moderate‑to‑severe atopic dermatitis, with a 71.0% mean EASI reduction at Week 16 versus 33.8% on placebo and 66.9% of patients achieving EASI‑75 versus 24.6% on placebo.
Zumilokibart and other antibodies in the portfolio show extended half-lives of 55 to 77 days, supporting dosing every three to six months and favorable safety profiles across early trials. Apogee is also advancing combination programs APG279 (IL‑13 + OX40L) and APG273 (IL‑13 + TSLP), and APG808 targeting IL‑4Rα, across atopic dermatitis, asthma, eosinophilic esophagitis and COPD.
The aggregate market value of non‑affiliate equity was approximately $1,757.9 million as of June 30, 2025. As of February 23, 2026, Apogee had 69,485,247 common shares outstanding, split between 55,998,605 voting and 13,486,642 non‑voting shares.
Apogee Therapeutics reported a larger full-year 2025 net loss of $255.8 million, up from $182.1 million in 2024, as it increased investment in its pipeline. Research and development expenses rose to $214.7 million and general and administrative expenses to $70.9 million.
The company ended 2025 with cash, cash equivalents and marketable securities totaling $902.9 million, and it believes this will fund operations into the second half of 2028. Key zurmilokibart (APG777) milestones include APEX Phase 2 Part A 52-week data expected in March, Part B data in Q2 2026, and Phase 3 initiation in atopic dermatitis in the second half of 2026, alongside a head-to-head APG279 trial versus DUPIXENT with results expected in the second half of 2026.
RTW Investments, LP and its managing partner Roderick Wong, M.D. report beneficial ownership of Apogee Therapeutics common stock. They disclose indirect control over 2,712,097 shares, representing 4.9% of the outstanding common stock, based on 54,833,587 shares outstanding as of November 3, 2025.
The shares are held by RTW-managed funds, with RTW and Dr. Wong sharing voting and dispositive power and no sole authority. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Apogee Therapeutics.
Apogee Therapeutics, Inc. chief executive Michael Thomas Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 11, 2026, he executed three open-market sales of Apogee common stock: 11,494 shares at a weighted average price of $62.96, 7,551 shares at $63.73, and 955 shares at $64.99.
The filing notes that these trades were made pursuant to a Rule 10b5-1 plan adopted on August 13, 2025, and that prices reflect weighted averages across multiple transactions within specified ranges. Following the last reported sale, Henderson directly beneficially owns 1,172,987 shares of Apogee common stock.
Michael Henderson filed a Form 144 indicating an intent to sell 60,000 shares of APGE common stock. The planned sale is through The Charles Schwab Corporation and is tied to an aggregate market value of $3,840,000, with an approximate sale date of February 11, 2026 on the Nasdaq.
The notice states these shares were acquired via RSU vesting between June 2, 2023 and December 14, 2023, with 60,000 securities acquired on June 2, 2023. The filing notes that 54,833,587 shares of the issuer’s common stock were outstanding. Over the prior three months, Henderson reported selling 40,000, 20,000 and 20,000 APGE common shares for gross proceeds of $3,000,312, $1,507,650 and $1,622,186, respectively.
Apogee Therapeutics, Inc. received an updated ownership report from several Wellington entities disclosing a sizeable institutional stake in its common stock. The Wellington group reports beneficial ownership of 4,746,585 shares of Apogee common stock, representing 8.66 % of the outstanding class.
The filing states Wellington has no sole voting or dispositive power over these shares. Instead, it reports shared voting power over up to 4,341,936 shares and shared dispositive power over up to 4,746,585 shares, held of record by Wellington investment-advisory clients in the ordinary course of business.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported an option exercise and related share sales. On 02/04/2026, he exercised stock options for 4,125 shares of common stock at an exercise price of $22.86 per share.
On the same date, he sold multiple small blocks of Apogee common stock at weighted average prices of $64.88, $65.83, $66.85, $67.88 and $68.94 per share, under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he directly held 211,148 shares of common stock and 135,415 derivative securities (stock options) of Apogee Therapeutics.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, she sold 792 shares of common stock at a weighted average price of $65.21, 1,108 shares at $66.15, and 100 shares at $66.89.
The weighted average prices reflect multiple trades in ranges from $64.80 to $65.61 and from $65.84 to $66.75. After these transactions, she directly owned 183,371 shares of Apogee common stock.
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.
Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.
Apogee Therapeutics, Inc. insider filing shows a major share sale by an investment fund linked to company directors. Fairmount Healthcare Fund II L.P., managed by Fairmount Funds Management LLC, sold 1,750,000 shares of Apogee common stock on 01/22/2026 at $76.30 per share in an indirect transaction. After this sale, the fund is reported as indirectly holding 298,647 shares of common stock.
The filing also reports that Fairmount Healthcare Fund II L.P. indirectly holds 6,743,321 shares of non-voting common stock, which are convertible into Apogee common stock on a 1-for-1 basis, subject to a beneficial ownership cap of 9.99%, which can be increased to up to 19.99% with 61 days’ notice. Separately, director-affiliated individuals Tomas Kiselak and Peter Harwin are each shown as indirectly holding 51,166 shares of common stock. Fairmount, Kiselak, and Harwin disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.